Review: Neoadjuvant Dual ICIs Offer Better Response Than Anti-PD1 Monotherapy in High-Risk Resectable Melanoma
Source: AJMC, March 2024
An alternative dose of ipilimumab and nivolumab had less toxicity than a conventional dose, the results show.
A pooled analysis of clinical trials conducted over a 5-year period shows that combining nivolumab (Opdivo) and ipilimumab (Yervoy) as neoadjuvant therapy increased the likelihood of pathologic and radiologic responses among patients with high-risk resectable melanoma than treatment with anti-PD1 monotherapy.
The review also found that an alternative dose of the combination, which relies more on nivolumab, the PD-1 inhibitor, causes fewer grade 3/4 immune-related adverse effects (irAEs) than a conventional dose that relies more on ipilimumab, which targets CLTA-4. The alternative dose offered no disruption in radiologic or pathologic efficacy, wrote authors of the review, which appeared Thursday in JAMA Oncology.